An Uphill Battle for Biosimilar Adoption in the U.S.

Posted by Varun Naik on Feb 26, 2018 6:00:23 PM

Biosimilars were expected to spark competition and lower prices for branded biologics, but this potential has still been unfulfilled. The U.S. health industry has been relatively slow to adopt biosimilars due to a combination of complex market access tactics employed by branded biologics manufacturers, on-going patent litigation, lack of interchangeability, and a general lack of awareness and acceptance of biosimilars. To date, the FDA has approved nine biosimilars; however, only three biosimilars have launched. The current biosimilars landscape is in stark contrast to the generics market where payers and pharmacy benefit managers promote these cheaper alternatives to reduce healthcare costs.

Read More

Topics: Market Analysis, Pharma, Healthcare, Pharmaceuticals

Supply Chain Shifts in the Ever-Tumultuous Health Industry

Posted by Robert Flynn on Jan 19, 2018 3:33:19 PM

Capitalism has its flaws. Economists as diverse as Adam Smith to Karl Marx would agree to this premise. Yet one strength that capitalism brings to bear in the marketplace is efficiency, particularly the ability to identify and capture substitute products and services when supply and demand constrains efficient market activity. Nowhere is this dynamic more apparent than in the seemingly ever-tumultuous health industry.

Read More

Topics: Competitive Intelligence, Pharma, Scenario Analysis, Competitive Strategy, Robert Flynn, Pharmaceuticals

Pharmaceutical Perspective: Considerations When Tapping into A New Market

Posted by Malini Solanki on Sep 14, 2017 10:15:52 AM

The U.S. is the largest market for pharmaceuticals, accounting for 30 to 40 percent of the worldwide market. However, newer smaller markets are on the rise for new drug products.

Read More

Topics: New Market Entry, Pharma

The Importance of Brand Awareness in the Pharmaceutical Industry

Posted by Neha Suri on May 10, 2017 10:15:38 AM

Co-Written by Karl Varkey

Today’s reality for pharmaceutical companies is anything but care free. Competition from the generics market continues to rise, the FDA’s approvals of new drugs has declined, and resolution of the debate surrounding the Affordable Care Act is uncertain. Additionally, the new administration has called for pricing restraints. This is certainly enough to cause angst among the most experienced pharmaceutical executives.

Read More

Topics: Brand Insights, Market Analysis, Pharma, Competitive Strategy

Fake News and Competitive Strategy

Posted by Malini Solanki on Jan 3, 2017 1:54:02 PM

The diagnostic industry provides essential information for healthcare, and is driven by medical technology, the aging population, and the complexity of disease. One sector, the global blood testing market, in 2015 was valued at $51.5 billion and is expected to grow to $62.9 billion by 2024. Understanding how to craft strategy in this market is critical, given the funding required for new ventures, and it is nuanced, given the often unusual business practices that can be employed by one's competitors. 

Read More

Topics: Competitive Intelligence, Pharma, Competitive Strategy

Upcoming Event: Robert Flynn Speaking at Pharma CI US Conference & Exhibition September 14th

Posted by Fuld + Company on Aug 23, 2016 9:19:47 AM

Join us this month at the Pharma CI Conference & Exhibition taking place September 13th - 14th at the Hilton Parsippany in Parsippany, New Jersey.

The Pharma CI Conference & Exhibition is the largest assembly of senior level pharmaceutical, biotech, and medical device professionals seeking the latest news and the chance to network with all the industry’s luminaries.

Members of our Life Sciences team will be at our booth to find out how we can address your competitive intelligence and strategy development needs in the pharmaceutical, biotech, medical device, and diagnostics industries. Robert Flynn, Principal, Strategic Accounts, will be giving a talk on early warning through scenario planning on Wednesday, September 14th.

Read More

Topics: Competitive Intelligence, Early Warning Monitoring, Fuld + Company, Pharma, Scenario Analysis

Medication-Induced Syndromes Offer Growth Opportunity

Posted by Kyle Nicholson on Aug 15, 2016 1:40:17 PM

Opioid-induced constipation, tardive dyskinesia, and other medication-induced syndromes present worthwhile revenue opportunities for pharmaceutical R&D.

In the 1960s, researchers discovered that the loss of motor control from Parkinson’s disease (PD) was tied to a deficiency of dopamine in a part of the brain involved in the coordination of movement.

Evidence soon established that administration of levodopa, a dopamine precursor molecule, dramatically improved PD symptoms. Here’s the catch: relief of symptoms was accompanied by severe nausea and vomiting. Levodopa was not only being converted to dopamine in the brain but also in the bloodstream, activating dopamine receptors in the peripheral nervous system and causing the adverse side effects.

Read More

Topics: Pharma, Life Sciences, Product Positioning, Competitive Strategy

Teva Membership in PhRMA Benefits Brand-Name Pharma

Posted by Steve Ames on Jul 12, 2016 10:53:02 AM

Teva, the world’s largest producer of generic medications, recently requested membership into Pharmaceutical Research and Manufacturers of America (PhRMA), the powerful US trade association of brand-name medicine manufacturers.

PhRMA is a lobby powerhouse, largely due to representation from most of the biggest players in the pharmaceutical industry. As detailed in the New York Times, Teva’s request ruffled the feathers of some PhRMA members who see Teva (and other generics companies) as a threat to the success of branded medicine. Brand-name and generic drug companies are no strangers to court battles against each other, typically around brand patent validity and timelines for generic entrance.

Read More

Topics: Innovation, Pharma, Life Sciences, Competitive Strategy

Defending Market Share in Pharma

Posted by Fuld + Company on Mar 18, 2016 9:49:49 AM

Pharmaceutical firms frequently need to defend their market position against rivals’ competitive strategy. Threats to leading therapies can come in many forms:

Read More

Topics: Competitive Intelligence, Fuld + Company, Pharma, Healthcare, Life Cycle Management, Life Sciences, Competitive Strategy

Filgotinib: Still Early to Pop the Champagne

Posted by Adi Reske on Dec 24, 2015 12:38:39 PM

Recently, Galapagos NV and Gilead entered a partnership, potentially worth more than $2 billion, to develop Galapagos’s oral JAK1 inhibitor, filgotinib, for inflammatory diseases.

Earlier in December 2015, Galapagos announced positive interim Phase II Crohn’s disease results for filgotinib. Based on the data presented, 48% of moderate to severe CD patient treated with filgotinib achieved clinical remission at 10 weeks compared to 23% placebo (p=0.0067); clinical response (CDAI decrease of 100 points or more) as well improvement in patients’ quality of life were also met in the study. According to the company’s CEO, results from the Phase II trial merit moving the drug into a Phase III Crohn's program “as soon as possible”.

Read More

Topics: Brand Insights, Pharma, Life Sciences, Product Positioning

Fuld + Company Blog

The material on this page draws on the research and experience of Fuld + Company thought leaders, consultants and others. Learn more about our expertise here.

Recent Posts

Request for Information

If you'd like someone at Fuld to contact you regarding your strategic competitive challenges, fill out the form below.